Impact Factor
1.84
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
0.35
96 total citations
h5-index
7
h5 depth signal
Cited share
22.6%
65 of 287
Total citations
96
Citation footprint
Metric signal
0.36
External metric anchor
Self-citation
0.0%
0 self-citations
Citations Trend
Monthly Publications Cadence
Citing Fields of Research
Oncology
51
Allergies
51
Pharmacology & Toxicology
45
Diabetes
41
Virology
39
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
532
Articles tracked across the journal lifetime
Indexed publication set
287
65 cited publications
Last 12 months
123
10.3 publications/month
Open access share
0.0%
0 OA publications in the last year
Leading citing country
N/A
No country analytics available
Leading citing field
Oncology
51 citing publications
Latest tracked publication
26 October 2026
10 recent records available
Coverage & Indexing History
v7n1, Jan. 1, 1965-
v7n1, Jan. 1, 1965-
Active Coverage
Active Coverage
Research Focus & Classification
Indexed Subjects
Allergies
Virology
Diabetes
Hematology
Neurodegenerative Disorders
Cardiology
Antibiotic & Antibacterial Agents
Broad Categories
Drug Therapy
Pharmacology
Therapeutics
Allergies
Hematology
Virology
Medical Ethics
Diabetes
Lymphomas
Urology
MeSH Descriptors
Drug Therapy
Pharmaceutical Preparations
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.58347/tml.2026.1766f
Open DOI
Zidesamtinib (Jideytro) – Another Kinase Inhibitor for NSCLC
Zidesamtinib (Jideytro – GSK), an oral kinase inhibitor, has been approved by the FDA for treatment of locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) in adults who received at least one prior ROS1 kinase ...
02
DOI 10.58347/tml.2026.1766e
Open DOI
Iberdomide (Zenbexus) for Multiple Myeloma
Iberdomide (Zenbexus – BMS), an oral first-in-class cereblon-modulating protein degrader, has received accelerated approval from the FDA for use in combination with the CD38-directed cytolytic antibody daratumumab (Darzalex Faspro) and d...
03
DOI 10.58347/tml.2026.1766d
Open DOI
In Brief: An Expanded Indication for Afrezza
The rapid-acting inhaled human insulin Afrezza (MannKind), which was approved in 2014 for treatment of type 1 or type 2 diabetes in adults, has now been approved by the FDA for use in children ≥6 years old.
04
DOI 10.58347/tml.2026.1766b
Open DOI
Tezepelumab (Tezspire) for Nasal Polyps
The FDA has approved tezepelumab (Tezspire – Amgen/AstraZeneca), a subcutaneously administered thymic stromal lymphopoietin (TSLP) blocker, for add-on maintenance treatment of inadequately controlled chronic rhinosinusitis with nasal pol...
05
DOI 10.58347/tml.2026.1766a
Open DOI
2026-2027 COVID-19 Vaccination
The FDA has licensed 2026-2027 formulas of the mRNA COVID-19 vaccines Comirnaty, Spikevax, and mNEXSPIKE1 and the adjuvanted protein subunit COVID-19 vaccine Nuvaxovid. The vaccines are FDA-licensed for use in adults ≥65 years old and in...
06
DOI 10.58347/tml.2026.1766c
Open DOI
Camizestrant (Etcamah) for Advanced Breast Cancer
Camizestrant (Etcamah – AstraZeneca), an oral estrogen receptor antagonist, has received accelerated approval from the FDA for use in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor for treatment of hormone receptor (HR)-p...
07
DOI 10.58347/tml.2026.1765c
Open DOI
Gedatolisib (Revtorpyk) for Breast Cancer
The kinase inhibitor gedatolisib (Revtorpyk – Celcuity) has been approved by the FDA for use in combination with fulvestrant, with or without the cyclin-dependent kinase (CDK) 4/6 inhibitor palbociclib (Ibrance), for treatment of hormone...
08
DOI 10.58347/tml.2026.1765e
Open DOI
Vusolimogene Oderparepvec (Tudriqev) – An Oncolytic Viral Therapy for Melanoma
Vusolimogene oderparepvec (Tudriqev – Replimune), a genetically-modified herpes simplex virus type 1 (HSV-1) oncolytic therapy, has been granted accelerated approval by the FDA for use in combination with the programmed death receptor-1 ...
09
DOI 10.58347/tml.2026.1765b
Open DOI
In Brief: A Cardiovascular Indication for Tirzepatide (Mounjaro)
The injectable GIP/GLP-1 receptor agonist tirzepatide (Mounjaro – Lilly), which was approved by the FDA in 2022 for treatment of type 2 diabetes,1 has now been approved to reduce the risk of MACE in adults with type 2 diabetes who are at...
10
DOI 10.58347/tml.2026.1765d
Open DOI
Lunsotogene Parvec (Otarmeni) for Hearing Loss
Lunsotogene parvec (Otarmeni – Regeneron), an adeno-associated viral vector-based gene therapy, has received accelerated approval from the FDA for treatment of severe-to-profound or profound sensorineural hearing loss (any frequency >90 ...
Bibliographical & Catalog Notes
Vols. 1-6 reissued in one volume in 1965.
Issues have also whole numbering.
Also issued online.
Vol. 37, no. 943 (MAR 1995)19950523 Notice not published Printed on acid-free paper